Proto-Oncogene Proteins c-bcl-6
"Proto-Oncogene Proteins c-bcl-6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A DNA-binding protein that contains an N-terminal BTB (POZ) DOMAIN and C-terminal CYS2-HIS2 ZINC FINGERS. It represses GENETIC TRANSCRIPTION of target genes by recruiting HISTONE DEACETYLASES. Aberrant Blc-6 expression is associated with certain types of human B-CELL LYMPHOMA.
| Descriptor ID |
D051560
|
| MeSH Number(s) |
D12.776.260.660 D12.776.624.664.700.170 D12.776.930.715
|
| Concept/Terms |
Proto-Oncogene Proteins c-bcl-6- Proto-Oncogene Proteins c-bcl-6
- Proto Oncogene Proteins c bcl 6
- c-bcl-6, Proto-Oncogene Proteins
- B-Cell Lymphoma 6 Protein
- B Cell Lymphoma 6 Protein
- Zinc Finger Protein 51
- c-bcl-6 Protein
- c bcl 6 Protein
- bcl-6 Proto-Oncogene Proteins
- Proto-Oncogene Proteins, bcl-6
- bcl 6 Proto Oncogene Proteins
- c-bcl-6 Proto-Oncogene Proteins
- Proto-Oncogene Proteins, c-bcl-6
- c bcl 6 Proto Oncogene Proteins
- Proto-Oncogene Protein bcl-6
- Proto Oncogene Protein bcl 6
- bcl-6, Proto-Oncogene Protein
- Proto-Oncogene Protein c-bcl-6
- Proto Oncogene Protein c bcl 6
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-bcl-6".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-bcl-6".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-bcl-6" by people in this website by year, and whether "Proto-Oncogene Proteins c-bcl-6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-bcl-6" by people in Profiles.
-
The Clinicopathologic Features and Molecular Signatures of Blastoid High-Grade B Cell Lymphoma, Not Otherwise Specified. Mod Pathol. 2023 Dec; 36(12):100349.
-
Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma. Cancer Discov. 2023 05 04; 13(5):1144-1163.
-
EBV+ high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study. Histopathology. 2022 Feb; 80(3):575-588.
-
Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole? Leuk Lymphoma. 2022 05; 63(5):1034-1044.
-
Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge. Mod Pathol. 2022 03; 35(3):419-426.
-
The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma. 2021 06; 62(6):1361-1369.
-
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020 03; 10(3):440-459.
-
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019 07 09; 12(1):73.
-
Characterization of Transcriptional Regulatory Networks that Promote and Restrict Identities and Functions of Intestinal Innate Lymphoid Cells. Immunity. 2019 07 16; 51(1):185-197.e6.
-
Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). Am J Clin Oncol. 2019 03; 42(3):304-316.